Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple injection dissolve painful calcium lumps in rare diseases?

NCT ID NCT03582800

Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 injections over six months, and doctors measure changes in deposit size using CT scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sodium thiosulfate injected under the skin
What this could lead to
If it works, this could offer a non-surgical option to shrink painful calcium deposits in rare diseases like systemic sclerosis and dermatomyositis.
What could go wrong
This is a small, early-phase pilot study with no placebo group, so results may not be definitive. The injections may not shrink deposits or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient presenting with: * ectopic ossification secondary to iPPSD2 or * ectopic calcification secondary to dermatomyositis or * ectopic calcification secondary to systemic sclerosis * Patient aged 2 years or over * Indication of STS infusion validated by a multidisciplinary committee, based on the significant morbidity and/or functional impact of the targeted calcification/ossification * Patient with no planned surgery of the calcifications/ossifications for the twelve coming months * Women of childbearing potential on highly effective contraception (such as hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence) * Men with women of childbearing potential partners should use condoms during the whole treatment period and until 91 days after the last injection. * Informed consent signed by the patient / parents * Patient affiliated to the social security system Exclusion Criteria: * Allergy to STS or one of the excipients used * Contraindication to local injection of STS * Anticoagulant therapy * Pregnant, parturient or breastfeeding woman * Patient deprived of freedom by a court judgment or an administrative decision * Patient undergoing psychiatric care under coercion * Legally protected adult patients (guardianship / curatorship) * Patient unable to give consent * Patient placed under judicial protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatomyositis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha-heavy chain disease dermatomyositis Ossification, Heterotopic pseudohypoparathyroidism type 1A systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatomyositis IPPSD2 Systemic sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ApHp - Hôpital Bicêtre

    RECRUITING

    Le Kremlin-Bicêtre, 94270, France

  • ApHp - hôpital Lariboisière

    RECRUITING

    Paris, 75000, France

  • CHU de BORDEAUX

    RECRUITING

    Bordeaux, 33000, France

  • CHU de Limoges

    RECRUITING

    Limoges, 87042, France

  • CHU de ROUEN

    NOT_YET_RECRUITING

    Rouen, 76031, France

  • CHU de Toulouse

    RECRUITING

    Toulouse, 31000, France

  • Hospice Civil de Lyon

    NOT_YET_RECRUITING

    Bron, 69500, France

  • Hôpital de la Pitié Salpétriêre

    NOT_YET_RECRUITING

    Paris, 75651, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.